Business
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
Patent expected to be formally granted within three months, subject to standard administrative proceduresPatent would provide exclusivity at least into 2039 for stenoparib when used in concert with the stenoparib DRP test TARPON SPRINGS, Fla., April 27, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today announced th
About this update from Allarity Therapeutics, Inc.
[{"type":"image","alt":"Allarity Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Allarity Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/16a0c0de99db65c057c520e53af4186e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZWz91jG0GlKDMeDFLyVrBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5Mw--/https://media.zenfs.com/en/globenewswire.com/16a0c0de99db65c057c520e53af4186e","width":300,"height":138}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Patent expected to be formally granted within three months, subject to standard administrative procedures","length":105,"tagName":"p"}]},{"val":[{"type":"text","content":"Patent would provide exclusivity at least into 2039 for stenoparib when used in concert with the stenoparib DRP test ","length":116,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":221,"olType":false},{"type":"text","content":"TARPON SPRINGS, Fla., April 27, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application covering the Company’s DRP® companion diagnostic specific to stenoparib.","length":467,"tagName":"p"},{"type":"text","content":"Importantly, this Notice of Allowance covers multiple claims and represents a major step in Allarity’s global strategy to expand and protect the commercial potential of stenoparib when selecting patients using its proprietary stenoparib DRP® test. The patent is expected to be formally granted within three months, subject to standard administrative procedures and would provide exclusivity at least into 2039 for stenoparib when used in concert with the DRP® as a companion diagnostic.","length":486,"tagName":"p"},{"type":"text","content":"Thomas Jensen, CEO of Allarity Therapeutics, commented: “This Notice of Allowance from the USPTO represents another successful milestone in our efforts to secure intellectual property protection for our DRP® technology in the US, the world’s most important pharmaceutical market. Critically, this patent maximizes the market...